Promising results on the use of the iBiopsy® platform in the context of measuring the anti-tumor immune response
Median Technologies today announced the promising results of a first retrospective study on the implementation of the iBiopsy® platform for the analysis of patients with solid tumor cancer who are likely to be responsive to immuno-oncology treatments such as those based on immune checkpoint inhibitors (ICIs)
Read more